Experience using cefpirome in patients with infections of the bronchopulmonary system
Abstract
The clinical efficacy and tolerance of cefpirome were estimated in the treatment of patients with bacterial infection of the respiratory tract. The estimate included 15 patients with acute and chronic bronchopulmonary diseases: 6 patients with acute pneumonia, 5 with exacerbated chronic purulent obstructive bronchitis and 4 with primary immune deficiency (agammaglobulinemia and acute pneumonia). Excellent and good total efficacy of the drug was stated in 6 and 8 patients respectively. In 1 patient the treatment was discontinued because of acute urticaria. Therefore, cefpirome is to be recommended as a highly efficient agent for the treatment of bronchopulmonary infection.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 15 participants or records.
Read the paper
Related studies
- Impact of antibiotics on the human microbiome and consequences for host health
- Antibiotics in the clinical pipeline in October 2019
- The incidence of collagen-associated adverse events in pediatric population with the use of fluoroquinolones: a nationwide cohort study in Taiwan
- Research Communications of the 32nd ECVIM-CA Online Congress
- Singlet-Oxygen Therapy. Scientific And Methodological Materials
- Artificial Intelligence in Pharmacovigilance
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.